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The aim of this study was to gain better insight into molecular
changes which reflect disturbances in the balance between pro-
liferation and apoptosis during progression of thyroid malignancy
from papillary microcarcinoma (PMC) via clinically manifest pap-
illary carcinoma (PTC) to anaplastic carcinoma (ATC).The apop-
tosis related molecules (Bcl-2, Bax) and proliferation related
marker (PCNA) were analysed immunohistochemically in 120
archival cases comprising PMC (n=34), PTC (n=52) and ATC
(n=34).In addition,in situ apoptotic cell death was analysed by
the TUNEL method.The average Bcl-2 staining score did not dif-
fer between PMC and PTC (p>0.05), but was significantly lower
in ATC (p<0.05).The Bax score was higher in PTCs and ATCs than
in PMCs (p<0.05). Due to these changes, the Bcl-2/Bax ratio
showed a marked decrease from PMC to ATC (p<0.05), while
proliferation activity increased significantly from PTC to ATC
(p<0.05).Despite high Bax expression,the rate of apoptotic cell
death was low in the investigated carcinomas, especially in ATC,
i.e. the increase in proliferative activity was not counterbalanced
with appropriate cell death.Differences were found in the expres-
sion of apoptotic molecules (Bcl-2 and Bax), their ratio (Bcl-2
/Bax) and in the rate of apoptotic cell death and  proliferative
activity between PMC,PTC and ATC,indicating  that disturbances
in the balance between apoptosis and proliferation, in favour of
the latter,occur gradually during the progression of malignancy in
thyroid tumours.
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T
hyroid cancer is not a common malignancy,
but it presents with many intricate aspects
concerning clinicopathological features and
tumour biology. These tumours originate from
either the follicular epithelial cells or the parafol-
licular cells. Carcinomas originating from follicu-
lar epithelium are generally classified into two
groups: well-differentiated thyroid carcinomas,
which are composed of papillary and follicular
carcinomas, and undifferentiated/anaplastic thy-
roid carcinomas.
Papillary thyroid carcinoma (PTC) is the most
common thyroid cancer and accounts for approxi-
mately 80% of all thyroid malignancies.Generally,
PTC grows slowly and despite its high potential for
regional nodal metastazation, it usually exhibits
rather non-aggressive biological behavior and has
a good prognosis.PTC can present in different his-
tological variants, as well as in various sizes (Li
Volsi, 1990; Rosai et al., 1992; Mazzaferri and
Jhiang, 1994; Mizukami et al., 1995; Gillilland et
al., 1997).PTCs that are not larger than 1 cm are
classified as papillary microcarcinomas - PMCs
(Hedinger  et al., 1988) and they are the most
common subtype of PTC. These lesions are fre-
quently detected as incidental findings on autopsy
or during examination of benign conditions. Most
of them remain silent clinically and have an excel-
lent prognosis. However, PMC may also represent
the earliest form of a future large lesion, since all
advanced carcinomas were microcarcinomas at
some point in the past. Thus, the relationship
between clinically evident PTC and PMC is not
completely clear and many questions concerning
the biological behaviour and, consequently, clinical
management of PMC, still remain unanswered
(Piersanti et al., 2003; Roti et al., 2006; Pelizzo
et al., 2006; Baloch and Li Volsi, 2006).
Contrary to PTCs which are generally indolent
slow-growing carcinomas,anaplastic thyroid carci-
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               noma (ATC) is one of the most aggressive human
malignancies known, characterized by an almost
invariable rapid fatal outcome. Despite vigorous
treatment, patients with ATC have a dismal prog-
nosis, mainly due to the high rates of nodal and
distant metastases and to local aggressiveness
(Aldinger et al., 1978; Li Volsi, 1990; Guiffrida
and Gharib, 2000). ATC is thought to arise from
a background of differentiated (papillary or follic-
ular) carcinoma, since many ATCs are accompa-
nied by such cells.Thus,ATC represents a terminal
dedifferentiation of preexisting differentiated car-
cinoma, i.e. the end stage of thyroid tumour pro-
gression (Spires et al., 1988; van der Laan et al.,
1993).
Molecular and genetic changes underlying the
progression of malignancy in thyroid tumours
from PMC via PTC to ATC are still not clear and
are under investigation. It is known that the bio-
logical behavior of each tumour depends on a
number of factors, including the rate of growth.
This in turn is related to the number of proliferat-
ing cells vs. those cells dying via necrosis or apop-
tosis, i.e. programmed cell death. Thus, the bal-
ance between proliferation and apoptosis may
play a major role in determining the growth and
aggressiveness of the tumour (Rubin et al., 2003).
Members of the Bcl-2 family play an important
role in the regulation of apoptosis (reviewed by
Burlacu, 2003 and Kirkin et al., 2004).The rep-
resentative member, Bcl-2, is a protein of the
outer mitochondrial membrane with anti-apoptot-
ic activity.The Bcl-2 homologue,Bax,a monomer-
ic cytosolic protein,displays a pro-apoptotic func-
tion.The Bax gene is transcriptionally activated by
p53, a tumour suppressor, now firmly established
as a key inhibitory regulator of cell proliferation
(Levine  et al., 1991). If unsuccessful, p53 can
also eliminate cells through the Bcl-2/Bax apop-
totic pathway. The ratio between Bcl-2 and Bax
appears to be important in deciding the life or
death of a cell (Reed, 1994).
The aim of this study was to gain better insight
into molecular changes that reflect disturbances
in the balance between proliferation and apoptosis
during progression of thyroid malignancy from
PMC via PTC to ATC. For this purpose we exam-
ined the expression of apoptosis related molecules
(Bcl-2, Bax) and of proliferation marker (PCNA)
and furthermore analysed in situ apoptotic cell
death in these tumours.
Materials and Methods
Tissue samples 
Formalin-fixed paraffin-embedded tissues were
obtained from the archival material of the Centre
for Endocrine Surgery, Clinical Centre of Serbia,
Belgrade. A total of 120 cases included: 34 cases
taken from patients diagnosed as having PMC
after undergoing surgery for benign or autoim-
mune conditions, 52 cases diagnosed as conven-
tional PTC and 34 cases diagnosed as ATC.
Histological slides from the thyroid tumor tissue
stained by haematoxylin and eosin were reevaluat-
ed by the pathologist to confirm the diagnosis of
papillary or anaplastic carcinoma, respectively,
according to widely accepted cytohistological cri-
teria (Li Volsi,1990;Rosai et al., 1992;Hedinger
et al., 1998).
Nuclear features (ground glass nuclei, grooved
nuclei and nuclear pseudoinclusions, at least two
of them), regardless of the growth pattern, were
taken as the “gold standard” for confirming the
diagnosis of papillary carcinoma. Selected  cases
included classical variant with papillary architec-
ture and follicular variant (including areas with a
solid growth pattern in some cases). Uncommon
subtypes of papillary carcinoma (such as oncocyt-
ic, tall cell, columnar) were excluded. Selected
cases were divided into two categories: papillary
microcarcinoma (PMC) and clinically manifest
papillary carcinoma (PTC).
Cytological features (large polygonal or spindle
shape cells, frequently multinucleated and con-
taining abnormal mitotic figures) confirmed the
diagnosis of ATC.
The study protocol was approved by the Ethics
Committee at the Centre for Endocrine Surgery,
Clinical Centre of Serbia, Belgrade.
Immunohistochemistry
For immunohistochemical staining we used
mouse monoclonal antibodies against human Bcl-
2 (clone Bcl 2-100, Sigma, Germany)  and PCNA
(NCL-PCNA, Novocastra, UK) and rabbit poly-
clonal antibody against Bax (Dako, Carpinteria,
California, USA).
Immunohistochemistry was performed using the
avidin-biotin-peroxidase method, provided by a
commercially available kit, according to the man-
ufacturer’s recommendations (Vector
Laboratories, Burlingame, California, USA).
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fin–embedded tissue block prepared previously
was used. Tissue sections (4-6 µm thick) from
each block were mounted on adhesive-coated
slides, deparaffinized with xylene and rehydrated
through a series of descending graded ethanol.
Endogenous peroxidase activity was blocked with
0.3% H2O2/methanol for 30 min followed by incu-
bation with non-immune horse serum for 20 min
to block non-specific binding.Tissue sections were
then incubated with primary antibody against Bcl-
2 (1:200 dilution), primary antibody against Bax
(1:25 dilution) or primary antibody against
PCNA (1:100 dilution) at 4°C overnight.This was
followed by incubation with biotinylated horse
anti-mouse IgG (for Bcl-2 and PCNA) or with
biotinylated goat-anti rabbit IgG (for Bax) for 30
min and thereafter with the avidin-biotin-peroxi-
dase complex  for 30 min.Between each step,sec-
tions were washed three times in phosphate
buffered saline (PBS).The reaction was visualised
using 3, 3’-diaminobenzidine tetra hydrochloride
(DAB) solution as a chromogen.
After counterstaining with haematoxylin, slides
were dehydrated in ascending ethanol, cleared
with xylene, mounted with coverslips using a per-
manent mounting medium and thereafter exam-
ined using a Reichart-Jung microscope supplied
with a Photostar automatic camera system.
Sections of normal human lymph nodes served
as a positive control for Bcl-2. In addition normal
thyroid tissue adjacent to malignant cells served
as an internal positive control for Bcl-2 and as a
negative control for Bax and PCNA.Tissue sam-
ples receiving no primary antibody (anti-Bcl-2,
anti-Bax or anti-PCNA), i.e. the antibody was
replaced with PBS during staining procedure,
exhibited no staining. and served as negative con-
trols.
Scoring of immunohistochemical staining 
Cytoplasmic staining for Bcl-2 and Bax was
scored by two independent observers as follows: (-,
0) no staining; (+/-, 1) weak or focal staining; (+,
2) moderate staining in the majority of cells and
(++, 3) strong staining in the majority of cells.
The Bcl-2/Bax ratio was estimated as follows:the
average staining scores for Bcl-2 and for Bax were
calculated (mean ± SD) from the individual stain-
ing score for each case (0-3) in the group and used
to estimate Bcl-2/Bax ratios.
PCNA  nuclear staining was scored as follows:
(0) no staining, (1) up to 10% stained nuclei, (2)
more than 10% and less than 25% stained nuclei
and (3) more than 25% stained nuclei.
The average staining score for PCNA was calcu-
lated (mean ± SD) from the individual staining
scores for each case in the group,and assigned as a
Proliferative index (PI).
In situ detection of apoptotic cells
Apoptotic cells in tissue sections were detected by
the terminal deoxynucleotidyl transferase-mediated
deoxy uridine triphosphate nick-end labeling tech-
nique (TUNEL), using a commercial apoptosis kit
(TACS TM TdT Kit, R&D Systems Europe,
Abington,UK), according to the supplier’s instruc-
tions. In brief, tissue sections were deparaffinized
with xylene and ethanol and rinsed with PBS.
Sections were then treated with proteinase K in
PBS, followed by quenching of endogenous peroxi-
dase. Digoxigenin-dUTP was added to the 3’-OH
ends of DNA by terminal deoxynucleotidyl trans-
ferase (TdT). After incubating with anti-digoxigen
antibody conjugated with peroxidase, the sections
were stained with diaminobenzidine (DAB) and
counterstained with methyl green.
Experimental controls included during perform-
ing the protocol of the TUNEL method were:TACS-
Nuclease-treated thyroid tissue sections as a posi-
tive control and the omission of TdT reaction step
as a negative control, according to supplier’s
instructions.
The percentage of apoptotic cells was determined
by light microscope examination and the rate of
apoptosis was graded as follows: (0) no detectable
apoptotic cells, (1) up to 10% apoptotic cells, (2)
more than 10% and less than 25% apoptotic cells
and (3) more than 25% apoptotic cells.
The average apoptotic score was calculated
(mean ± SD) from the individual staining scores for
each case in the group, and assigned as an
Apoptotic index (AI).
The ratio between proliferation and apoptosis
(PI/AI ratio)
The ratio between proliferation and apoptosis was
estimated as follows: the average staining scores
for proliferative and for apoptotic cells were calcu-
lated (mean ± SD) from the individual staining
score for each case in the group and used to esti-
mate proliferation/apoptosis  ratio (PI/AI ratio).
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Statistical comparisons of data were made using
Pearson's χ
2 test and the Mann-Whitney U-test, as
indicated in the Results section. A value p<0.05
was considered to be statistically significant.
Results
Immunohistochemical expression of Bcl-2 and
Bax proteins was visualized as cytoplasmic staining
and found in most of the carcinomas examined
(Table 1).There was no statistically significant dif-
ference in Bcl-2 expression between PMC and PTC
(94.12% positive cases and 92.31% positive
cases, respectively), but the number of Bcl-2 posi-
tive cases was lower in the ATC group (76.47%,
p<0.05).
Bax positivity was significantly higher in PTCs
(92.31%) than in PMCs (73.53%, p<0.05).There
was no difference in the number of Bax positive
cases between PTCs and ATCs.
Since Bcl-2 and Bax positive carcinomas showed
variability in immunostaining pattern, the average
staining scores for both Bcl-2 and Bax were calcu-
lated (mean ± SD) from the individual staining
score for each case (0-3) in the group.Thereafter,
the Bcl-2/Bax ratio was estimated from those val-
ues (Table 2). The Bcl-2 score did not differ
between PMC and PTC (1.971 and 1.923, respec-
tively). ATC cases showed a significantly lower
average Bcl-2 score than PMCs and PTCs
(p<0.05). The average Bax score was markedly
higher in PTCs (2.481) than in PMCs (1.706,
p<0.05), but there was no significant difference
between PTCs and ATCs.Due to the changes in the
level of Bcl-2 and Bax expression during malignan-
cy progression from PMC to ATC, the Bcl-2/Bax
ratio decreased from 1.155 in PMC to 0.586 in
ATC (p<0.05).
Immunohistochemical expression of PCNA
revealed a significant enhancement from PMC to
ATC (Figure 1 A,B,C).The relative number of high
PCNA expressing cases (scores 2 and 3) was
35.39% for PMC, 53.85% for PTC and 82.35%
for ATC (p<0.05). As shown in Table 3, the mean
proliferation index (PI) for the analyzed carcinoma
groups increased significantly (p<0.05) from PMC
via PTC to ATC (PI=1.118, 1.615 and 2.412,
respectively).
The number of apoptotic cells was low, with zero
up to ten positive cells per 10 HPFs in most carci-
nomas studied (Figure 1 D, E, F). The apoptotic
index (AI) for each carcinoma group is given in
Table 3 and was similar in PMCs and PTCs (0.441
and 0.500, respectively), but significantly less in
ATCs (0.206,p<0.05).The ratio between prolifera-
tion and apoptotic indices (PI/AI) increased signif-
icantly during progression from PMC (PI/AI =
2.535) to ATC (PI/AI = 11.719, p<0.05). There
was a weak association between the decreased Bcl-
2 expression and decreased apoptosis but no rela-
tion with Bax expression (statistically not signifi-
cant).
Discussion 
The thyroid gland represents an exceptional
opportunity to study the regulation of proliferation
and apoptosis during tumour initiation and progres-
sion from a precursor lesion (PMC) through a clin-
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Table 1. Immunohistochemical expression of Bcl-2 and Bax in papillary microcarcinoma (PMC), papillary carcinoma (PTC) and anaplas-
tic carcinoma (ATC) of the thyroid gland.
Bcl-2 Bax
- +/- + ++ - +/- + ++
PMC (n = 34) 2 6 17 9 9 4 9 12
Bcl-2 positive: 32/34  (94.12%) Bax positive: 25/34 (73.53%)c
PTC (n = 52) 4 9 26 13 4 2 12 34
Bcl-2 positive: 48/52 (92.31%)a Bax positive: 48/52 (92.31%)d
ATC (n = 34) 8 17 8 1 3 5 11 15
Bcl-2 positive: 26/34 (76.47%)b Bax positive: 31/34 (92.12%)
Staining score: (-,0) no staining;  (+/-,1) weak or focal staining; (+,2)  moderate staining in the majority of cells; (++,3) strong staining in the majority of cells.
Statistically significant difference (p<0.05) for a vs b and c vs d (Pearson's χ
2 test).ically manifest slow-growing tumour (PTC) to a
fatal rapidly growing carcinoma (ATC).The biolog-
ical behaviour of these subtypes of thyroid cancer is
highly divergent, as reflected by differences in their
prognoses (indices of morbidity and mortality),pat-
terns of metastasis and “clinical aggressiveness”.
Besides other factors,tumour growth and aggres-
siveness depend on the ratio between anti-apoptot-
ic and pro-apoptotic molecules and their balance
with the proliferative activity of neoplastic cells.
Therefore, in this study we analysed expression of
the apoptosis related molecules, Bcl-2 and Bax,
their ratio, in situ apoptotic cell death and prolifer-
ative activity during progression of thyroid malig-
nancy from PMC via PTC to ATC.
Bcl-2 is an anti-apoptotic molecule that prevents
apoptosis by preserving mitochondrial membrane
integrity (Gross et al., 1999;Burlacu,2003;Kirkin
et al., 2004). In previous reports, Bcl-2 was found
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Figure 1. Proliferation and
apoptosis in papillary microcar-
cinoma (PMC), clinically mani-
fest papillary carcinoma (PTC)
and anaplastic carcinoma
(ATC) of the thyroid gland.
Proliferative activity, assessed
by PCNA immunohistochemical
staining, in PMC (A, bar 30
µm), PTC (B, bar 30 µm) and
ATC (C, bar 30 µm).
Streptavidin-biotin immunoper-
oxidase technique, haema-
toxylin diaminobenzidine coun-
terstaining.  In situ apoptotic
cell death in PMC (D, bar 30
µm), PTC (E, bar 20 µm) and
ATC (F, bar 10 µm). TUNEL
technique, methyl green coun-
terstaining. 
Table 2. The average immunostaining score for Bcl-2 and Bax
and the Bcl-2/Bax ratio* in papillary microcarcinoma (PMC),
papillary carcinoma (PTC) and anaplastic  carcinoma (ATC) of
the thyroid gland.
Bcl-2 score Bax score Bcl-2/Bax
PMC (n = 34) 1.971±0.834 1.706±1.219c 1.155e
PTC (n = 52) 1.923±0.860
a 2.481±0.897d 0.775   
ATC (n = 34) 1.241±0.776
b 2.118±0.977 0.586f
*Estimated as detailed in the Material and Methods section. Statistically significant dif-
ferences (p<0.05) for a vs b, c vs d, e vs f  (Mann-Whitney U-test).
Table 3. Proliferation and apoptotic indices in papillary micro-
carcinoma (PMC), papillary thyroid carcinoma (PTC) and
anaplastic thyroid carcinoma (ATC) as assessed by PCNA
immunostaining and the TUNEL method.
Proliferation index (PI)* Apoptotic index (AI)* PI/AI*
PMC (n= 34) 1.118±0.769a 0.441±0.504 2.535  
PTC (n = 52) 1.615±0.867b 0.500±0.505d 3.230f
ATC (n = 34) 2.412±0.925c 0.206±0.411e 11.719g
*As detailed in the Material and Methods section. Statistically significant differences
(p<0.05) for a vs b, b vs c, d vs e, f vs g (Mann-Whitney U-test).to be expressed in normal thyroid tissue and in well
differentiated thyroid carcinomas (Moore et al.,
1988; Pilotti  et al., 1994; Pollina  et al., 1996;
Mitselou et al., 2004;Aksoy et al., 2005;Cvejic et
al., 2008;Xu et al., 2007,2008),but its expression
was reported to decrease with dedifferentiation and
aggressiveness (Moore et al., 1988; Pollina et al.,
1996; Saltman et al., 2006).
The pro-apoptotic molecule Bax has been less
investigated in thyroid carcinomas, with conflicting
results, and its role in thyroid tumorigenesis and
tumour biology is discussed controversially. While
some authors could not detect Bax in well differen-
tiated thyroid carcinomas (Manetto et al., 1997),
others reported Bax expression in all or in the
majority of PTCs investigated (Hermann et al.,
2001; Letsas et al., 2005). In anaplastic thyroid
carcinoma, Bax was found to be weakly expressed
(Branet et al., 1996).
The results of this study showed significant
changes in the expression of apoptosis–related mol-
ecules during progression of malignancy in thyroid
tumours. Bcl-2 protein was present at similar high
levels in PMC and PTC, but decreased significant-
ly during progression to anaplastic carcinoma,
which confirms previous results. On the contrary,
the expression of Bax protein increased in PTC
when compared to PMC, and thereafter was main-
tained at a similar level in ATC.
Due to these changes,the Bcl-2/Bax ratio showed
a significant decline during progression of malig-
nancy from PMC to ATC. It is assumed that the
ratio of Bcl-2 and Bax decides whether a cell will
undergo apoptosis or not, i.e. Bax/Bcl-2 and
Bax/Bax dimers are able to prolong cell life and
induce cell death,respectively (Reed,1994).In this
study, In situ detection of apoptotic cells indicated
a low apoptotic index in both papillary carcinoma
types, as reported previously (Yoshida et al., 1999;
Farid et al., 2001;Letsas et al., 2005).This is con-
sistent with high levels of Bcl-2, the anti-apoptotic
molecule.On the other hand,Bcl-2 prolongs cell life
span and allows further mutations to accumulate,
facilitating tumour progression from microscopic
(subclinical) to clinically apparent carcinomas
(PTCs), which are, as shown here, characterized by
concomitant expression of Bcl-2 and Bax,
increased proliferative activity and a low rate of
apoptosis.Finally,the transition of the phenotype of
well-differentiated papillary carcinoma to anaplas-
tic carcinoma is a very rare event,requiring further
sequential mutations in genes involved in growth
signal transduction cascades, cell cycle regulation
and apoptotic pathways due to genomic instability.
Our results showed that this terminal phase of
malignancy progression is characterized by perma-
nent accelerated proliferative activity,a low level of
Bcl-2 and a high level of Bax, but with a very low
rate of apoptotic death.
However, an increase in apoptotic cell death in
ATC compared to well-differentiated thyroid carci-
noma was reported by Moore et al. (1988) for two
cases analyzed, and also by Sreelekha et al.
(2000), but the levels of Bax protein expression
were not evaluated. It could be expected that the
loss of Bcl-2 and an accumulation of Bax homod-
imers should lead to a higher rate of apoptosis.
However,the reasons for inappropriate cell death in
thyroid carcinomas, despite the presence of high
levels of pro-apoptotic Bax protein are not yet
understood.Thus, the complexity of genetic defects
in the apoptotic pathway in thyroid carcinomas, for
example defects in functions of Bax downstream
effectors, such as caspases, should be investigated.
In contrast to the low level of apoptosis, prolifer-
ative activity in this study was shown to increase
significantly during progression from PMC to ATC,
and consequently the ratio between proliferation
and apoptotic indices was shifted in favor of prolif-
eration.
In conclusion, in this investigation we found dif-
ferences in the expression of apoptotic molecules
(Bcl-2 and Bax), their ratio (Bcl-2 /Bax), apoptot-
ic cell death and proliferative activity between
PMC,PTC and ATC,indicating that disturbances in
the balance between apoptosis and proliferation, in
favour of the latter, occur gradually during the pro-
gression of malignancy in thyroid tumours.
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